CFM
BBIO icon

Catalyst Funds Management’s BridgeBio Pharma BBIO Stock Holding History

Catalyst Funds Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,800
Closed -$117K – 1194
2024
Q1 		$117K Buy
+3,800
New +$129K 0.03% 366

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Catalyst Funds Management's BBIO Position: Q2 2024 in Review

Catalyst Funds Management sold out of BridgeBio Pharma (BBIO) in Q2 2024, closing a stake of 3,800 shares — an estimated $117K sold.

Catalyst Funds Management first reported a position in BBIO in Q1 2024 and held it in 1 quarter. The position peaked at $117K in Q1 2024. 251 funds tracked by Wall St. Rank hold BBIO as of Q2 2024.

  • Catalyst Funds Management reported no remaining BridgeBio Pharma position as of Q2 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 3,800 BridgeBio Pharma shares in Q2 2024, an estimated $117K.
  • Catalyst Funds Management first reported a position in BridgeBio Pharma in Q1 2024 and held it in 1 quarter.
  • Catalyst Funds Management's BridgeBio Pharma position peaked at $117K in Q1 2024.
  • 251 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2024.

Based on Catalyst Funds Management's 13F filing for Q2 2024, filed 18 Dec 2024.